These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26886327)

  • 1. Do We Bury Antibacterials When Launching? Cefaclor Example.
    Tomić Z; Tomas A; Vukmirović S; Mikov M; Horvat O; Tomić N; Sabo A
    J Pharm Sci; 2016 Mar; 105(3):1295-300. PubMed ID: 26886327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
    Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PK-PD modelling of the effect of cefaclor on four different bacterial strains.
    de la Peña A; Gräbe A; Rand KH; Rehak E; Gross J; Thyroff-Friesinger U; Müller M; Derendorf H
    Int J Antimicrob Agents; 2004 Mar; 23(3):218-25. PubMed ID: 15164961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
    Cazzola M; Di Perna F; Boveri B; Di Marco F; Diamare F; Centanni S
    J Chemother; 2000 Jun; 12(3):216-22. PubMed ID: 10877516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
    Schentag JJ
    Scand J Infect Dis Suppl; 1990; 74():218-34. PubMed ID: 2097710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
    Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I
    Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ; Marchillo K; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice.
    Wicha SG; Mundkowski RG; Klock A; Hopt UT; Drewelow B; Kloft C; Wellner UF; Keck T; Wittel UA
    J Clin Pharmacol; 2019 Oct; 59(10):1405-1414. PubMed ID: 31111505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
    Mouton JW; Ambrose PG; Canton R; Drusano GL; Harbarth S; MacGowan A; Theuretzbacher U; Turnidge J
    Drug Resist Updat; 2011 Apr; 14(2):107-17. PubMed ID: 21440486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Jan; 50(1):243-9. PubMed ID: 16377693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of cefaclor in respiratory infections amongst Pakistani children.
    Najam Y; Walla FL; Iqbal A; Khan MK; Aqil S; Sharif MW; Masood T; Gaba I; Malik BA; Hassan M; Malik S; Hassan S; Bukhari KA; Khawar N; Tarar MA
    J Pak Med Assoc; 2000 Sep; 50(9):289-93. PubMed ID: 11043017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
    VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics.
    Jacobs MR
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S122-6. PubMed ID: 17936592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.
    Deguchi T; Nakane K; Yasuda M; Shimizu T; Monden K; Arakawa S; Matsumoto T
    Int J Antimicrob Agents; 2010 Jun; 35(6):573-7. PubMed ID: 20226636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.